The Four Ws of the Fourth Dose COVID-19 Vaccines: Why, Who, When and What

被引:6
|
作者
Khong, Ka-Wa [1 ]
Zhang, Ruiqi [1 ]
Hung, Ivan Fan-Ngai [1 ,2 ,3 ]
机构
[1] Univ Hong Kong, Li Ka Shing Fac Med, Dept Med, Hong Kong, Peoples R China
[2] Univ Hong Kong, Li Ka Shing Fac Med, State Key Lab Emerging Infect Dis, Hong Kong, Peoples R China
[3] Univ Hong Kong, Li Ka Shing Fac Med, Carol Yu Ctr Infect, Hong Kong, Peoples R China
关键词
COVID-19; vaccine; booster dose; Omicron variant; OMICRON VARIANT; MESSENGER-RNA; TRANSPLANT RECIPIENTS; NON-INFERIORITY; SINGLE-BLIND; VACCINATION; INFECTION; ANTIBODY; RESPONSES; IMMUNITY;
D O I
10.3390/vaccines10111924
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
With the emergence of SARS-CoV-2 variants, vaccine breakthrough is a major public health concern. With evidence of reduced neutralizing antibody activity against Omicron variants and fading antibody level after the third-dose booster vaccine, there are suggestions of a fourth-dose booster vaccine. In this review, the benefits of a fourth-dose booster is evaluated from four perspectives, including the effectiveness of the booster dose against virus variants (Why), susceptible groups of individuals who may benefit from additional booster dose (Who), selection of vaccine platforms to better enhance immunity (What) and appropriate intervals between the third and fourth booster dose (When). In summary, a fourth dose can temporarily boost the immune response against SARS-CoV-2 variants and can be considered for specific groups of individuals. A heterologous vaccine strategy using mRNA vaccine in individuals primed with inactivated vaccine may boost immunity against variants. The timing of the fourth dose should be individualized but an interval of 4 months after the third-dose booster is appropriate. A universal fourth booster dose is not necessary.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Computed tomography chest in COVID-19: When & why?
    Garg, Mandeep
    Prabhakar, Nidhi
    Bhalla, Ashu Seith
    Irodi, Aparna
    Sehgal, Inderpaul
    Debi, Uma
    Suri, Vikas
    Agarwal, Ritesh
    Yaddanapudi, Laxmi Narayana
    Puri, Govardhan Dutt
    Sandhu, Manavjit Singh
    [J]. INDIAN JOURNAL OF MEDICAL RESEARCH, 2021, 153 (1-2) : 86 - 92
  • [42] When, how, why and whom for there will be an "after" Covid-19?
    Tognoni, Gianni
    [J]. ASSISTENZA INFERMIERISTICA E RICERCA, 2020, 39 (03) : 147 - 153
  • [43] Humoral and cellular immune memory to four COVID-19 vaccines
    Zhang, Zeli
    Mateus, Jose
    Coelho, Camila H.
    Dan, Jennifer M.
    Moderbacher, Carolyn Rydyznski
    Galvez, Rosa Isela
    Cortes, Fernanda H.
    Grifoni, Alba
    Tarke, Alison
    Chang, James
    Escarrega, E. Alexandar
    Kim, Christina
    Goodwin, Benjamin
    Bloom, Nathaniel, I
    Frazier, April
    Weiskopf, Daniela
    Sette, Alessandro
    Crotty, Shane
    [J]. CELL, 2022, 185 (14) : 2434 - +
  • [44] Fourth COVID-19 Vaccine Dose Increases Low Antibodies
    Abbasi, Jennifer
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (06): : 517 - 517
  • [46] COVID-19 vaccines and treatments: When speed is necessary and not enough
    Grasela, Thaddeus H.
    Price, David A.
    Wagner, John A.
    [J]. CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (04): : 1201 - 1205
  • [47] Booster doses for inactivated COVID-19 vaccines: if, when, and for whom
    Croda, Julio
    Ranzani, Otavio T.
    [J]. LANCET INFECTIOUS DISEASES, 2022, 22 (04): : 430 - 432
  • [48] Vaccines against COVID-19 and ethics: when will it be my turn?
    Roman Maestre, Begona
    [J]. JOURNAL OF HEALTHCARE QUALITY RESEARCH, 2021, 36 (02) : 57 - 58
  • [49] Expected Usefulness of Fourth Dose of COVID-19 Vaccine for Patients with Underlying Solid Tumor who Previously Received the Primary Heterologous COVID-19 Vaccine
    Yasri, Sora
    Wiwanitkit, Viroj
    [J]. INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2024, 45 (04) : 301 - 305
  • [50] COVID-19 Vaccines
    不详
    [J]. US PHARMACIST, 2021, 46 (02)